Back to resultsStudy of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Primary Purpose
Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Tislelizumab
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral T Cell Lymphoma focused on measuring T/NK-cell, NK/T-cell, extranodal, nasal, NK-cell, ENKTL, peripheral T-cell, anaplastic large cell, ALCL, angioimmunoblastic, PTCL-NOS, Relapsed, Refractory
Eligibility Criteria
Key Inclusion Criteria
- Confirmed diagnosis of relapsed or refractory extranodal NK/T-cell lymphoma (nasal or non-nasal type, peripheral T-cell lymphoma - not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, or Sezary syndrome)
- Age 18 years or older
- Relapsed or refractory to at least 1 prior systemic therapy
- Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) for participants in Cohort 1 and 2
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Life expectancy ≥ 6 months
- Adequate respiratory function
- Adequate bone marrow function
- Adequate renal and hepatic function
Key Exclusion Criteria
- Known central nervous system (CNS) involvement by lymphoma
- Previously received immune checkpoint therapy
- Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 or lower prostate cancer
- Active autoimmune disease or history of autoimmune diseases that may relapse with some exceptions
- Severe or debilitating pulmonary disease
- Clinically significant cardiovascular disease
- Active fungal, bacterial, and/or viral infection requiring systemic therapy
- Known infection with HIV or active viral hepatitis B or C infection
- Major surgery within 4 weeks of the first dose of study drug
- Pregnant or lactating women
- Vaccination with a live vaccine within 35 days prior to the first dose of study drug
- Hypersensitivity to tislelizumab
- Concurrent participation in another therapeutic clinical trial
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Sites / Locations
- UBC - British Columbia Cancer Agency - The Vancouver Centre
- Peking University Third Hospital
- Beijing Hospital
- Peking Union Medical College Hospital
- Fujian Medical University Union Hospital
- Sun Yat-Sen University Cancer Center
- He Nan Cancer Hospital
- Affiliated Tumor Hospital of Harbin Medical University
- The First Affiliated Hospital of Soochow University
- The affiliated hospital of Xuzhou medical university
- Fudan university Shanghai Cancer Center
- Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
- West China Hospital of Sichuan University
- Tianjin Cancer Hospital
- Zhejiang Cancer Hospital
- Institut d'hématologie de Basse Normandie
- Centre hospitalier Universitaire de Limoges
- Centre hospitalier Lyon Sud
- Universitätsmedizin Göttingen
- Universitätsklinikum Halle
- Universitätsklinikum Leipzig AöR
- Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi
- Ospedale Maggiore, AOU Parma
- Ospedale Policlinico San Martino - IRCCS per l'Oncologia
- ASST Papa Giovanni XXII
- Ospedale San Raffaele
- A.O.U. Pisana, Stabilimento di Santa Chiara
- Azienda Ospedaliera Santa Maria di Terni
- National Cheng Kung University Hospital
- National Taiwan University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Cohort 1: ENKTL
Cohort 2: PTCL-NOS, AITL, and ALCL
Cohort 3: MF and SS
Arm Description
Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Participants with other R/R mature T-cell neoplasms [limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Participants with R/R cutaneous T-cell lymphoma [limited to mycosis fungoides (MF) and Sèzary syndrome (SS)] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Outcomes
Primary Outcome Measures
Overall Response Rate (ORR)
ORR is defined as the percentage of participants achieving a best overall response of complete response or partial response as determined by the investigator using Lugano criteria with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) modification for cohorts 1 and 2 and International Society for Cutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) guidelines for cohort 3.
Secondary Outcome Measures
Duration of Response (DOR)
DOR defined as the time from the first determination of an objective response until progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Progression-free Survival (PFS)
PFS is defined as the time from first study drug administration to the date of disease progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Overall Survival (OS)
OS defined as the time from first study drug administration to the date of death due to any reason for cohorts 1 and 2.
Complete Response Rate (CRR)
CRR is defined as the percentage of participants who achieve complete response or complete metabolic response as best overall response as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time to Response (TTR)
Time to response defined as the time from first study drug administration to the time the response criteria (complete response or partial response) are first met as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Quality of Life Assessment: EQ-5D-5L Change From Baseline in Visual Analogue Score
Mean change from baseline at safety follow-up visit in EQ-5D-5L visual analogue score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' An increasing score indicates improvements from baseline.
Quality of Life Assessment: EORTC QLQ-C30 Change From Baseline in Global Health Status Score
Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.
Quality of Life Assessment: EORTC QLQ-C30 Change From Baseline in Fatigue Score
Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Fatigue score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes questions related to fatigue symptoms in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically relevant changes in laboratory tests, physical examination, electrocardiogram, and vital signs
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03493451
Brief Title
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Official Title
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
April 13, 2018 (Actual)
Primary Completion Date
April 21, 2021 (Actual)
Study Completion Date
April 21, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BeiGene
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This was a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell neoplasms. There were three cohorts:
Cohort 1: Relapsed or refractory (R/R) extranodal NK/T cell lymphoma (ENKTL; nasal or non-nasal type)
Cohort 2: Other R/R mature T-cell neoplasms, limited to the following histologies: peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), or anaplastic large-cell lymphoma (ALCL)
Cohort 3: R/R cutaneous T-cell lymphoma, limited to mycosis fungoides (MF) or Sèzary syndrome (SS)
Study procedures included a Screening phase (up to 35 days); Treatment phase (until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first); Safety Follow-up phase (up to 90 days following last study treatment for all adverse events (AEs) and serious adverse events (SAEs)); and Survival follow-up phase (duration varying by participant).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory, Peripheral T-cell Lymphoma NOS, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma Refractory, Anaplastic Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, ALK-negative Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, Cutaneous T-cell Lymphoma
Keywords
T/NK-cell, NK/T-cell, extranodal, nasal, NK-cell, ENKTL, peripheral T-cell, anaplastic large cell, ALCL, angioimmunoblastic, PTCL-NOS, Relapsed, Refractory
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
77 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cohort 1: ENKTL
Arm Type
Experimental
Arm Description
Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Arm Title
Cohort 2: PTCL-NOS, AITL, and ALCL
Arm Type
Experimental
Arm Description
Participants with other R/R mature T-cell neoplasms [limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Arm Title
Cohort 3: MF and SS
Arm Type
Experimental
Arm Description
Participants with R/R cutaneous T-cell lymphoma [limited to mycosis fungoides (MF) and Sèzary syndrome (SS)] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Intervention Type
Drug
Intervention Name(s)
Tislelizumab
Other Intervention Name(s)
BGB-A317
Intervention Description
Administered intravenously
Primary Outcome Measure Information:
Title
Overall Response Rate (ORR)
Description
ORR is defined as the percentage of participants achieving a best overall response of complete response or partial response as determined by the investigator using Lugano criteria with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) modification for cohorts 1 and 2 and International Society for Cutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) guidelines for cohort 3.
Time Frame
Up to approximately 3 years and 1 week
Secondary Outcome Measure Information:
Title
Duration of Response (DOR)
Description
DOR defined as the time from the first determination of an objective response until progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time Frame
Up to approximately 3 years and 1 week
Title
Progression-free Survival (PFS)
Description
PFS is defined as the time from first study drug administration to the date of disease progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time Frame
Up to approximately 3 years and 1 week
Title
Overall Survival (OS)
Description
OS defined as the time from first study drug administration to the date of death due to any reason for cohorts 1 and 2.
Time Frame
Up to approximately 3 years and 1 week
Title
Complete Response Rate (CRR)
Description
CRR is defined as the percentage of participants who achieve complete response or complete metabolic response as best overall response as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time Frame
Up to approximately 3 years and 1 week
Title
Time to Response (TTR)
Description
Time to response defined as the time from first study drug administration to the time the response criteria (complete response or partial response) are first met as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.
Time Frame
Up to approximately 3 years and 1 week
Title
Quality of Life Assessment: EQ-5D-5L Change From Baseline in Visual Analogue Score
Description
Mean change from baseline at safety follow-up visit in EQ-5D-5L visual analogue score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' An increasing score indicates improvements from baseline.
Time Frame
Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)
Title
Quality of Life Assessment: EORTC QLQ-C30 Change From Baseline in Global Health Status Score
Description
Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.
Time Frame
Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)
Title
Quality of Life Assessment: EORTC QLQ-C30 Change From Baseline in Fatigue Score
Description
Mean change from baseline at safety follow-up visit in EORTC QLQ-C30 Fatigue score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes questions related to fatigue symptoms in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a higher score indicating improved health status.
Time Frame
Baseline and on Day 1 in Cycles 5, 9, 13, 17, 21, 25, 29, and 33 (21 days per cycle) and safety follow-up visit (up to 30 days after end of treatment; up to approximately 3 years and 1 week)
Title
Number of Participants With Adverse Events
Description
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically relevant changes in laboratory tests, physical examination, electrocardiogram, and vital signs
Time Frame
Up to approximately 3 years and 1 week
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria
Confirmed diagnosis of relapsed or refractory extranodal NK/T-cell lymphoma (nasal or non-nasal type, peripheral T-cell lymphoma - not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, or Sezary syndrome)
Age 18 years or older
Relapsed or refractory to at least 1 prior systemic therapy
Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) for participants in Cohort 1 and 2
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Life expectancy ≥ 6 months
Adequate respiratory function
Adequate bone marrow function
Adequate renal and hepatic function
Key Exclusion Criteria
Known central nervous system (CNS) involvement by lymphoma
Previously received immune checkpoint therapy
Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 or lower prostate cancer
Active autoimmune disease or history of autoimmune diseases that may relapse with some exceptions
Severe or debilitating pulmonary disease
Clinically significant cardiovascular disease
Active fungal, bacterial, and/or viral infection requiring systemic therapy
Known infection with HIV or active viral hepatitis B or C infection
Major surgery within 4 weeks of the first dose of study drug
Pregnant or lactating women
Vaccination with a live vaccine within 35 days prior to the first dose of study drug
Hypersensitivity to tislelizumab
Concurrent participation in another therapeutic clinical trial
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Study Director
Organizational Affiliation
BeiGene
Official's Role
Study Director
Facility Information:
Facility Name
UBC - British Columbia Cancer Agency - The Vancouver Centre
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada
Facility Name
Peking University Third Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100000
Country
China
Facility Name
Beijing Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
Peking Union Medical College Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
Fujian Medical University Union Hospital
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350001
Country
China
Facility Name
Sun Yat-Sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Facility Name
He Nan Cancer Hospital
City
Zhengzhou
State/Province
He Nan
ZIP/Postal Code
450008
Country
China
Facility Name
Affiliated Tumor Hospital of Harbin Medical University
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150000
Country
China
Facility Name
The First Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215006
Country
China
Facility Name
The affiliated hospital of Xuzhou medical university
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221002
Country
China
Facility Name
Fudan university Shanghai Cancer Center
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Name
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200092
Country
China
Facility Name
West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Facility Name
Tianjin Cancer Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300060
Country
China
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310022
Country
China
Facility Name
Institut d'hématologie de Basse Normandie
City
Caen
ZIP/Postal Code
14000
Country
France
Facility Name
Centre hospitalier Universitaire de Limoges
City
Limoges
ZIP/Postal Code
87000
Country
France
Facility Name
Centre hospitalier Lyon Sud
City
Pierre-Bénite
ZIP/Postal Code
69310
Country
France
Facility Name
Universitätsmedizin Göttingen
City
Göttingen
State/Province
Niedersachsen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Universitätsklinikum Halle
City
Halle
State/Province
Sachsen-Anhalt
ZIP/Postal Code
06120
Country
Germany
Facility Name
Universitätsklinikum Leipzig AöR
City
Leipzig
State/Province
Sachsen
ZIP/Postal Code
04103
Country
Germany
Facility Name
Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi
City
Bologna
State/Province
Emilia
ZIP/Postal Code
40138
Country
Italy
Facility Name
Ospedale Maggiore, AOU Parma
City
Parma
State/Province
Emilia
ZIP/Postal Code
43100
Country
Italy
Facility Name
Ospedale Policlinico San Martino - IRCCS per l'Oncologia
City
Genova
State/Province
Liguria
ZIP/Postal Code
16132
Country
Italy
Facility Name
ASST Papa Giovanni XXII
City
Bergamo
State/Province
Lombardia
ZIP/Postal Code
24127
Country
Italy
Facility Name
Ospedale San Raffaele
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20123
Country
Italy
Facility Name
A.O.U. Pisana, Stabilimento di Santa Chiara
City
Pisa
State/Province
Toscana
ZIP/Postal Code
56126
Country
Italy
Facility Name
Azienda Ospedaliera Santa Maria di Terni
City
Terni
State/Province
Umbria
ZIP/Postal Code
05100
Country
Italy
Facility Name
National Cheng Kung University Hospital
City
Tainan
ZIP/Postal Code
70403
Country
Taiwan
Facility Name
National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
10002
Country
Taiwan
12. IPD Sharing Statement
Plan to Share IPD
Yes
Citations:
Citation
Huiqiang Huang, et al. Tislelizumab (BGB-A317) for relapsed/refractory extranodal NK/T-cell lymphoma: preliminary efficacy and safety results from a phase 2 study. Poster Abstract EP1268, European Hematology Association 2020.
Results Reference
background
Citation
Pier Luigi Zinzani, et al. Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphomas: Safety and efficacy results from a phase 2 study. Poster Abstract EP1235, European Hematology Association 2020.
Results Reference
background
Learn more about this trial
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
We'll reach out to this number within 24 hrs